MediWound Slips After 1Q Loss Widens

Dow Jones

May 28

By Christopher Kuo

Shares of MediWound fell after the biopharmaceutical company's loss widened in the first quarter and regional conflict caused a decline in revenue.

The stock slid 7.2%, to $15.49, midday Wednesday, and is down 16% year to date.

The Israel company, which focuses on tissue repair, earlier Wednesday posted a first-quarter loss of $3 million, or 23 cents a share, compared with a loss of $726,000, or 7 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 65 cents a share.

Revenue fell to $1.5 million from $4 million a year earlier. Analysts expected $3.4 million. The decrease was primarily driven by the timing of Barda-related revenues and postponed shipments related to regional conflict, the company said.

The company's research-and-development expenses rose to $5.2 million from $2.9 million a year earlier, primarily due to higher costs from the EscharEx Value Phase 3 trial.

The company reaffirmed its full-year revenue guidance of $24 million to $26 million. Analysts expect full-year revenue of $24.8 million.

Write to Christopher Kuo at chris.kuo@wsj.com

(END) Dow Jones Newswires

May 27, 2026 12:39 ET (16:39 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2638682134"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2638682134\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2638682134?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-28 00:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638682134","market":"nz","top_or_hot":-1,"title":"MediWound Slips After 1Q Loss Widens","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of MediWound fell after the biopharmaceutical company's loss widened in the first quarter and regional conflict caused a decline in revenue. \n</p>\n<p>\n  The stock slid 7.2%, to $15.49, midday Wednesday, and is down 16% year to date. \n</p>\n<p>\n  The Israel company, which focuses on tissue repair, earlier Wednesday posted a first-quarter loss of $3 million, or 23 cents a share, compared with a loss of $726,000, or 7 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 65 cents a share. \n</p>\n<p>\n  Revenue fell to $1.5 million from $4 million a year earlier. Analysts expected $3.4 million. The decrease was primarily driven by the timing of Barda-related revenues and postponed shipments related to regional conflict, the company said. \n</p>\n<p>\n  The company's research-and-development expenses rose to $5.2 million from $2.9 million a year earlier, primarily due to higher costs from the EscharEx Value Phase 3 trial. \n</p>\n<p>\n  The company reaffirmed its full-year revenue guidance of $24 million to $26 million. Analysts expect full-year revenue of $24.8 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 27, 2026 12:39 ET (16:39 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MediWound Slips After 1Q Loss Widens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMediWound Slips After 1Q Loss Widens\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-28 00:39</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of MediWound fell after the biopharmaceutical company's loss widened in the first quarter and regional conflict caused a decline in revenue. \n</p>\n<p>\n  The stock slid 7.2%, to $15.49, midday Wednesday, and is down 16% year to date. \n</p>\n<p>\n  The Israel company, which focuses on tissue repair, earlier Wednesday posted a first-quarter loss of $3 million, or 23 cents a share, compared with a loss of $726,000, or 7 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 65 cents a share. \n</p>\n<p>\n  Revenue fell to $1.5 million from $4 million a year earlier. Analysts expected $3.4 million. The decrease was primarily driven by the timing of Barda-related revenues and postponed shipments related to regional conflict, the company said. \n</p>\n<p>\n  The company's research-and-development expenses rose to $5.2 million from $2.9 million a year earlier, primarily due to higher costs from the EscharEx Value Phase 3 trial. \n</p>\n<p>\n  The company reaffirmed its full-year revenue guidance of $24 million to $26 million. Analysts expect full-year revenue of $24.8 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 27, 2026 12:39 ET (16:39 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2638682134","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2638682134","pubTimestamp":1779899940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of MediWound fell after the biopharmaceutical company's loss widened in the first quarter and regional conflict caused a decline in revenue.The stock slid 7.2%, to $15.49, midday Wednesday, and is down 16% year to date.The Israel company, which focuses on tissue repair, earlier Wednesday posted a first-quarter loss of $3 million, or 23 cents a share, compared with a loss of $726,000, or 7 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 65 cents a share.Revenue fell to $1.5 million from $4 million a year earlier. Analysts expected $3.4 million. The decrease was primarily driven by the timing of Barda-related revenues and postponed shipments related to regional conflict, the company said.The company's research-and-development expenses rose to $5.2 million from $2.9 million a year earlier, primarily due to higher costs from the EscharEx Value Phase 3 trial.The company reaffirmed its full-year revenue guidance of $24 million to $26 million. Analysts expe","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","MDWD":"MediWound Ltd."},"translate_title":"MediWound在第一季度亏损扩大后下滑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDWD":1.5},"content_text":"By Christopher Kuo \n\n\n \n\n\n  Shares of MediWound fell after the biopharmaceutical company's loss widened in the first quarter and regional conflict caused a decline in revenue. \n\n\n  The stock slid 7.2%, to $15.49, midday Wednesday, and is down 16% year to date. \n\n\n  The Israel company, which focuses on tissue repair, earlier Wednesday posted a first-quarter loss of $3 million, or 23 cents a share, compared with a loss of $726,000, or 7 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 65 cents a share. \n\n\n  Revenue fell to $1.5 million from $4 million a year earlier. Analysts expected $3.4 million. The decrease was primarily driven by the timing of Barda-related revenues and postponed shipments related to regional conflict, the company said. \n\n\n  The company's research-and-development expenses rose to $5.2 million from $2.9 million a year earlier, primarily due to higher costs from the EscharEx Value Phase 3 trial. \n\n\n  The company reaffirmed its full-year revenue guidance of $24 million to $26 million. Analysts expect full-year revenue of $24.8 million. \n\n\n \n\n\n  Write to Christopher Kuo at chris.kuo@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 27, 2026 12:39 ET (16:39 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}